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Estudo SYNTAX: análise e implicações clínicas
The SYNTAX trial, presented in the congresses of the
European Society of Cardiology in Munich, Germany and
the European Association of Cardiothoracic Surgery in
Lisbon, Portugal in September 2008, is the first study to
compare the clinical results of the best technology of
percutaneous coronary interventions (PCI) using
pharmacological stents (paclitaxel-eluding stent – Taxus,
Boston Scientific Corp) with the best therapy currently
provided by coronary artery bypass surgery (CABG) in
patients with triple vessel coronary artery disease and/or
lesions of the left coronary artery trunk.
The study, carried out in 62 European and 23 American
centers and financed by the Boston Scientific Corporation,
the manufacturer of the Taxus stent, at a cost of
approximately 50 millions US dollars, intended to
demonstrate the hypothesis that the PCI-Taxus stent was
not inferior to CABG in patients with triple vessel disease
and/or lesions of the left coronary artery trunk.
The primary objective of the study was to analyze the
compound clinical outcome constituted of death by any
cause, strokes, myocardial infarction, the necessity of
repeated revascularization by PCI and/or CABG (defined
as MACCE - Major Cardiovascular or Cerebrovascular
Events) at 12 months of follow up.
Two types of study were formed, the first was
randomized and the other was a register. The randomized
study included patients that were eligible for both types of
procedure (by consensus between the heart surgeon and
the hemodynamicist). On the other hand, the register
included patients that were considered only eligible for
one of the two treatments.
A total of 3075 patients were enrolled, with 1800
presenting with the inclusion criteria for the randomized
study; 897 in the CABG Group and 903 in the PCI/Taxus
Arm. The other 1275 patients formed the SYNTAX register,
where the criterion was that only one treatment method
was possible. Thus, 1077 patients were allocated to the
Surgery Group and 198 to the PCI Group.
The final result of the SYNTAX trial confirmed that
CABG is better than PCIs with drug-eluting stents for this
population of high-risk patients. In 12 months, 17.8% of
the patients in the PCI/Taxus Group presented with the
compound outcome versus 12.1% of the surgical patients
with a statistically significantly difference (p = 0.0015).
Thus, an analysis of the SYNTAX trial is important not
only because of the result but also for the implications of
the findings.
Initially, as it was an “all comers” type study enabling
the inclusion of patients with characteristics closer to the
real world population, instead of being a classical controlled
randomized study with many exclusion criteria, it reflected
the current clinical practice.
Type of study
This non-inferior trial, which used predefined margins
of non-inferiority, attempts to determine that a new treatment
is not inferior to the reference treatment. Thus, the results
show that the new method is ‘slightly’ inferior to the
standard treatment. The null hypothesis of equality does
not apply to this type of test.
Nuances in statistical aspects of non-inferior studies
have been the source of criticism. When this type of
statistical method is combined with the use of several
compound outcomes and different classifications of adverse
events, non-inferiority studies are viewed with caution [1,2].
Mortality
The mortality rate at 12 months was 4.3% in the PCI
Group and 3.5% in the Surgical Group. The study was not
designed and did not have statistical power to analyze
differences in isolated outcomes. Nevertheless surgery
showed a strong tendency of improved survival over one
year, with a 23% benefit in respect to death compared to
PCI. This data is consistent with other studies of drug-
eluting stents versus CABG, such as the analysis of the
New York State register that demonstrated a significant
advantage of survival of CABG versus drug-eluting stents
over 18 months. This study identified a 21% relative benefit
in patients with triple vessel lesions and 35% relative benefit
in patients with lesions of two vessels [3].
A further evaluation that will occur after five years will
be important. Data of the SCAAR (Swedish Coronary
Angiography and Angioplasty Registry) study
demonstrated that mortality and myocardial infarction
increased between six months and three years in patients
submitted to PCI with Taxus stents when compared to
conventional stents [4].
Stent thrombosis and symptomatic graft occlusion
The thrombosis rate of Taxus stents at 12 months was
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3.3%, surprisingly higher than that found in controlled
randomized studies, where the rate of thrombosis of paclitaxel-
eluting stents over one year was 0.7% (by the protocol of
the study) or 0.8% (definitive or probable by the definition
of ARC - Academic Research Consortium) [5,6]. The use of
Taxus stents for long lesions and the number of implanted
stents contributed to the increased rate of long-term
thrombosis and complications (mean total length of implanted
stents = 86.1 ± 47.9 mm; 33.2% of patients had total length of
implanted stents greater than 100 mm).
On the other hand, the occlusion rate of symptomatic
grafts in the SYNTAX trial was 3.4% over 12 months. This
number is lower than that classically reported of 10% of
occlusion of venous grafts over one year [7]. A better
surgery technique allied to the intensive use of statins and
antiplatelet agents may be responsible for the difference in
these results.
The prognosis of these complications is also different.
In drug-eluting stent thrombosis, the mortality rate varies
between 30% and 45% and the occurrence of myocardial
infarction is greater than 80% [5,8].
Cost-effectiveness
The results of the cost-effectiveness of the SYNTAX
trial are awaited. To achieve complete revascularization, in
the PCI Group there was a necessity of the implantation of
4.6 Taxus stents per patient. With a unit value for the Taxus
stent in Brazil being around R$10,000.00 (about US
$23,500.00), the cost, just for the devices is R$46,000.00
(about US $108,300.00). The additional cost of the greater
necessity of further procedures and the continuous use of
clopidogrel must also be taken into account.
Strokes
The rate of strokes over 12 months was 2.2% in CABG
and 0.6% in the PCI Group. For the first time, an important
study comparing surgery with angioplasty has reported
this difference. The most obvious explanation is found in
the design of the SYNTAX trial, which includes a population
of more severe patients than those selected for controlled
randomized studies, which generally exclude patients with
more serious comorbidities.
The incidence of strokes after CABG is mainly related
to the age of the patient and the presence of atherosclerotic
plaque in the ascending and transverse aorta. Peri-operative
atheroembolism from the aorta is responsible for at least
one third of the cases of strokes after CABG due to the
handling of the ascending aorta or aortic arch during
cannulation, aortic clamping, preparation of proximal
anastomoses or of the arterial cannula flow. Recent more
rigorous methods to detect advanced atherosclerosis of
the ascending aorta, as well as surgical strategies, such as
the no-touch technique of off-pump surgery, may reduce
the mobilization of aortic atheroma and prevent the
occurrence of this event [9]. This finding reinforces the
fact that surgery in this group of more seriously ill patients
may evolve and improve the results.
Necessity of further revascularization
It has been demonstrated that drug-eluting stents are
capable of reducing restenosis and the necessity of
additional revascularization compared with the conventional
stent, based on the data of controlled randomized studies.
Nevertheless, when extrapolated to large national registers,
with groups of patients from the real world, the difference
is marginal. In the SCAAR trial, with a population more
similar to the one of this study, the absolute reduction in
restenosis rates between drug-eluting and conventional
stents was 3% and of re-interventions of 1%, thus lower
than rates in controlled randomized studies [4].
Anginal target
While CABG is effective in reducing angina, there are no
data about the efficacy of drug-eluting stents compared to
conventional stents in respect to angina. The comparative
data at one and five years of follow up will be awaited.
Subgroups
In the analysis of patients with trunk lesions, the total
MACCE at 12 months was lower with CABG (13.7% versus
15.8%). When stratified by diabetes, diabetic patients had
a lower MACCE at 12 months after CABG than after PCI-
Taxus (14.2% versus 26.0%).
Details of the operative technique
The mean number of grafts per patient was 2.8 and the
mean number of distal anastomoses per patient was 3.2.
Off-pump CABG was utilized in 15% of the patients,
reflecting the reality in most North American and European
centers that participated in the trial. Bilateral internal
thoracic artery grafts were utilized in 27.6% of patients and
complete arterial revascularization in 18.9%. However, it is
interesting to note that an arterial graft was used for the
anterior descending artery in 95.6% of the patients, not
100%, which should be the target in surgery. Complete
revascularization was performed in 63% of the patients
submitted to CABG against 57% in PCI.
SYNTAX register
Concomitantly, the results of the SYNTAX register were
presented; 1275 patients of a cohort of 3075 patients initially
selected (41.1% of the patients) and that were considered
eligible for only one type of procedure. Thus, 1077 patients
were allocated to the Surgical Group and 198 to the PCI Group.
This allocation was based on the clinical and anatomical
characteristics: patients who were not candidates for CABG
V(inoperative patients, n = 198) and patients who were not
candidates for PCI (technically impossible, n = 1077). The
main causes for ineligibility for CABG were severe
morbidities (70.7%), lack of grafts (9.1%) and coronary
arteries with bad quality distal beds (1.5%). In the PCI Group,
the main causes were complex coronary anatomy (70.9%),
chronic total occlusion of the coronary artery (22%) and
impossibility of antiplatelet therapy (0.9%).
In the results, the death rates by any cause were 2.5%
in CABG against 7.3% in PCI; myocardial infarction (2.5%
CABG vs. 4.2% PCI); stroke (2.2% CABG vs. 0% PCI);
compound death; stroke and myocardial infarction (6.6%
vs. 10.5% PCI); new revascularization (3.0% CABG vs. 12%
PCI); total MACCE (8.8% CABG vs. 20.4% PCI).
The final analysis of the register expresses the
conclusion that CABG continues to be the only option for
the treatment of at least 1/3 of patients enrolled with results
that are considered excellent. Surgery presents the
additional advantage of avoiding double antiplatelet
therapy indefinitely and the associated risk of bleeding.
SYNTAX score
In this prospective study, the SYNTAX score was
developed with the aim of stratifying patients for the best
procedure. The SYNTAX score is based on the coronary
anatomy in respect to the number of lesions and their
functional repercussions, location and complexity. Higher
SYNTAX scores are indicative of more complex conditions
and potentially worse prognoses.
Thus the application of the SYNTAX score demonstrated
that medium- and high-risk patients benefit from surgical
treatment. The patients with lower risk had similar benefits
from both procedures. This is indicative that lower-risk
patients fit into the characteristics of patients from the MASS-
2 and COURAGE studies and require additional evaluation
to determine the benefit of the procedures.
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